Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.
| Revenue (Most Recent Fiscal Year) | $9.09M |
| Net Income (Most Recent Fiscal Year) | $-156.43M |
| PE Ratio (Current Year Earnings Estimate) | 5.05 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 599.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2136.10% |
| Net Margin (Trailing 12 Months) | -2127.09% |
| Return on Equity (Trailing 12 Months) | -13.40% |
| Return on Assets (Trailing 12 Months) | -12.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 25.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | 0.64 |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.67 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.49 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 71.02M |
| Free Float | -- |
| Market Capitalization | $4.80B |
| Average Volume (Last 20 Days) | 551.90 |
| Beta (Past 60 Months) | 0.92 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |